Heyu Biological Technology Corporation
Heyu Biological Technology Corporation (HYBT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
hybt · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Heyu Biological Technology Corporation (HYBT) measures how much investors pay for each dollar of the company's trailing earnings. HYBT's current PE ratio of 241.19x is calculated by dividing its stock price of $0.35 by its TTM earnings per share of $0.00. +1110.8% elevated vs 5Y avg 19.9x
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 4 fiscal years · Front-end computedMinQ1 · 25%4.1x
MedianQ3 · 75%70.9x
Max
At 241.19x, HYBT's current P/E is higher than in 100% of its annual fiscal year readings over the past 4 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Heyu Biological Technology CorporationYou HYBT | $361M | 241.19x | +1501.3% | $0.00 |
 biote Corp. BTMD | $103M | 3.01x | -80.0% | $0.86 |
 NIOX Group Plc CSSPF | $274M | 40.40x | +168.2% | $0.02 |
 Dong Fang Hui Le Inc. DFHL | $400M | N/A | — | -$0.00 |
 Guerbet S.A. GUERF | $281M | 16.84x | +11.8% | $1.28 |
 Hamilton Thorne Ltd. HTLZF | $245M | N/A | — | -$0.00 |
 Orpea S.A. ORRRY | $372M | 0.00x | -100.0% | $848.01 |
Industry Average 4 peers with valid PE | — | 15.06x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-0.00 | — | |
2023-12-31 FY2023 | — | $-0.00 | — | |
2022-12-31 FY2022 | — | $-0.00 | — | |
2021-12-31 FY2021 | — | $-0.00 | — | |
2020-12-31 FY2020 | — | $-0.01 | — | |
2019-12-31 FY2019 | — | $-0.00 | — | |
2018-12-31 FY2018 | — | $-0.00 | — | |
2017-12-31 FY2017 | — | $-0.00 | — | |
2016-12-31 FY2016 | — | $-0.15 | — | |
2015-12-31 FY2015 | — | $-3.31 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Heyu Biological Technology Corporation (HYBT) measures how much investors pay for each dollar of the company's trailing earnings. HYBT's current PE ratio of 241.19x is calculated by dividing its stock price of $0.35 by its TTM earnings per share of $0.00.
Frequently asked questions
HYBT pe ratio · 6 questionsHYBT's current PE ratio is 241.19x as of 2026-06-08, based on a stock price of $0.35 and TTM EPS of $0.00. Data sourced from Financial Modeling Prep via HYBT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Heyu Biological Technology Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08